ReviewBiomolecules2026
Inorganic Polyphosphate in Hematolymphoid Malignancies: Biological Rationale and Emerging Research Gaps.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inorganic polyphosphates (polyP) are linear phosphate polymers that play essential functions in human physiology, such as coagulation and inflammation. Despite their recognized participation in solid tumor progression, there are few data on hematolymphoid malignancies. Here, we conducted a narrative review of studies investigating polyP functions in mammalian biology, coagulation, and hematologic systems, focusing on research gaps in hematological oncology. PolyP modulates coagulation cascades, platelet activation, and cellular metabolism. In tumors, polyP has been reported to modulate immune responses and apoptosis in several experimental systems. Emerging data suggest participation in leukemic signaling and the bone marrow microenvironment. Direct evidence linking polyP to hematolymphoid neoplasms is scarce. Being biologically plausible, it represents a promising and largely unexplored area of research and an excellent opportunity for novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.